Lars Ekman

Dr. Lars G.
Ekman is a Chairman-Emeritus at Prothena Corp.
Plc, an Executive Partner, Private Equity at Sofinnova Investments, Inc., a Chairman at AFYX Therapeutics AS, a Chairman at Prothena Biosciences, Inc. and a Chief Auditor at Codemill AB. He is on the Board of Directors at Prothena Corp.
Plc.
Dr. Ekman was previously employed as an Independent Director by Ultragenyx Pharmaceutical, Inc., an Independent Director by Spark Therapeutics, Inc., an Executive Chairman by Sophiris Bio, Inc., an Independent Director by OCERA Therapeutics LLC, a Non-Executive Director by Amarin Corp.
Plc, a Chief Executive Officer by Cebix, Inc., a Lead Independent Director by InterMune, Inc., a Non-Executive Director by Elan Corp.
Plc, an EVP, President-Research & Development by Elan Pharmaceuticals, Inc., an Executive Vice President-Research & Development by Schwartz Pharma AG, an Executive Vice President by Pharmacia GmbH, a Principal by Pharmacia Corp., and a Chairman by Poseida Therapeutics, Inc. He also served on the board at Ocera Therapeutics, Inc. /Old/ and ARYx Therapeutics, Inc. He received his doctorate degree from the University of Gothenburg.